

## **Lupin Receives US FDA Approval for Cefadroxil Capsules**

<b>BSE : 500257</b>	<b>NSE: Lupin</b>	<b>REUTERS: LUPN.BO</b>	<b>BLOOMBERG: LPC IN</b>
---------------------	-------------------	-------------------------	--------------------------

**Mumbai, 31<sup>st</sup> May 2007:** Lupin Ltd., announced today that it has received approval from the US FDA for its Abbreviated New Drug Application (ANDA) for Cefadroxil Capsules 500mg. Cefadroxil, a broad spectrum antibiotic, is used to treat infections caused by various bacteria.

Lupin's Cefadroxil Capsules are the AB-rated generic equivalent of Warner Chilcott (erstwhile) Duricef<sup>®</sup> Capsules. This approval augments the cephalosporin portfolio of the Company in the \$8.7 bn broad spectrum antibiotic market in the US.

With this approval, Lupin now has 23 ANDAs approved by the US FDA.

### **About Lupin**

Headquartered in Mumbai, Lupin Ltd. is a leading pharmaceutical company with strong research focus. It has a programme for developing New Chemical Entities. The Company has state-of-the-art R&D center in Pune. The Company is a leading global player in Anti-TB, Cephalosporins (anti-infectives) and Cardiovascular drugs (prils and statins) and has a notable presence in the areas of diabetology, NSAIDS and Asthma.

For the financial year ended March 2007, Lupin's Revenues and Profit after Tax were Rs.20,289 million (US\$ 475 million) and Rs. 3,021 million (US\$ 70 million) respectively.

### **For further information contact:**

Raju Kane

The Source

Tel. +91 22 24901327/28

Telefax: +91 22 24901325

Mobile: +91 98200 45656

E-mail: [rajukane@sourcepr.com](mailto:rajukane@sourcepr.com)